Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Hedge Funds Think About Ellington Financial LLC (EFC), Which Claims To Be Trading At A 17% Discount To Book Value

Page 1 of 2

Ellington Financial LLC (NYSE:EFC) announced yesterday in a press release that its estimated book value per common share is $23.04, or on a diluted basis, $22.75, as of June 30, 2015. However, Ellington Financial LLC (NYSE:EFC)’s stock closed at just $18.88 on Wednesday. This puts the stock at about a 17% discount to book value, which is indeed a big discount. Nonetheless, analysts at Zacks downgraded the specialty finance company to a ‘Strong Sell’ from a ‘Hold’ rating on July 7, which perhaps prompted the press release a day later, and investors have reacted with seeming apathy to Ellington’s assertions of its own value, with the stock trading only marginally up in afternoon trading today, by less than half a percentage point. Does the smart money see this untapped potential in the specialty financial company, which primarily manages mortgage-related assets? According to the data, not particularly.

Ellington Financial LLC (NYSE:EFC)

Looking at the hedge funds tracked by Insider Monkey, there was no change in the number of hedge funds with positions in the stock at the end of the first quarter, when compared to the prior quarter, as eight funds maintained positions in the stock. The aggregate capital invested by these hedge funds fell by around 3% meanwhile, to $75.08 million. Considering the fact that Ellington Financial LLC (NYSE:EFC)’s stock dropped by a minuscule 0.8% in the first three months of the year, we can say that hedge funds pulled a small amount of capital out of the stock during that time. Nor were they wrong to do so, as shares fell by 7% during the second quarter. Considering the fact that Ellington Financial happens to be an affiliate of Mike Vranos‘ Ellington Management Group, which holds over half of the shares collectively owned by hedge funds we track, we can say that the unaffiliated ownership is even far less than it appears at first glance.

Mike Vranos
Mike Vranos

Most investors don’t understand hedge funds and indicators that are based on hedge fund and insider activity. They ignore hedge funds because of their recent poor performance in the long-running bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns enjoyed (or not) by investors. We uncovered through extensive research that hedge funds’ long positions in small-cap stocks actually greatly outperformed the market from 1999 to 2012, and built a system around this. The 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 80 percentage points since the end of August 2012 when this system went live, returning a cumulative 135% vs. less than 55% for the S&P 500 Index (read the details).

Likewise, other research (not our own) has shown insider purchases are also effective piggybacking methods for investors. That’s why we believe investors should pay attention to what hedge funds and insiders are buying and keep them apprised of this information. That said, there was no insider activity on the stock during the first half of this year.

With all of this in mind, let’s take a look at the recent hedge fund activity surrounding Ellington Financial LLC (NYSE:EFC).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!